|
Effect of cisplatin intraperitoneal hyperthermic perfusion chemotherapy on apoptosis of human gastric cancer cell lines and its mechanism
Wang Fabao, Xia Zeliang, Chu Liang, Zhou Shaobo, Xu Zhaolong, Jiang Lei, Shan Erbo, Zhou Chaoyi
Journal of Shandong First Medical Unversity & Shandong Academy of Medical Sciences
2021, 42 (5):
396-400.
DOI: 10.3969/j.issn.2097-0005.2021.05.013
Objective: To preliminarily explore the effect of intraperitoneal hyperthermic perfusion of cisplatin on the apoptosis of human gastric cancer cell line (SGC-7901) and its mechanism.Methods: The four groups divided in the experiment were the control group, cisplatin group, hyperthermia group and hyperthermia chemotherapy group. CCK-8 was used to detect cell viability in each group, Hoechst staining method was used to detect cell apoptosis, flow cytometry was used to detect cell apoptosis rate, and Western blot was used to detect the expression levels of Caspase-3, Bcl-2, Bax and Bid proteins. Results: Compared with the control group, the cell viability of the cisplatin group, the hyperthermia group and the thermochemotherapy group was significantly reduced (
P<0.01), the apoptosis rate was significantly increased (
P<0.01), and the Caspase-3, Bax and Bid proteins were significantly increased High (
P<0.05 or
P<0.01), Bcl-2 expression was down-regulated (
P<0.01). Compared with the cisplatin group and the hyperthermia group, the cell viability of the thermochemotherapy group was significantly reduced (
P<0.05), the apoptosis rate was significantly increased (
P<0.05), and the Caspase-3, Bax and Bid proteins were significantly increased (
P<0.05), the expression of Bcl-2 was significantly down-regulated (
P<0.05). There was no significant difference between the cisplatin group and the hyperthermia group (
P>0.05). Conclusion: Cisplatin intraperitoneal hyperthermic perfusion chemotherapy can promote the apoptosis of SGC-7901 cells by promoting the expression of Caspase-3, Bax and Bid and down-regulating Bcl-2.
Reference |
Related Articles |
Metrics
|
|